Yingen Bio-B (09606.HK) announced that the company's directors and senior management are confident in the company's long-term value and future development prospects. The board of directors of the company learned that, based on this confidence, Chairman of the Board of Directors, Dr. Zhu Zhongyuan, Executive Director and Chief Financial Officer, Mr. Zhang Shaoren, Executive Director, Dr. Hua Haiqing, Executive Director, Senior Vice President and Chief Financial Officer, Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc., Dr. Mou Hua, Global Chief Medical Officer, Ms. Si Wen, Executive Director of Human Resources, Mr. Yu Xin, Vice President and Head of Regulatory Affairs, and Ms. Yuan Jiali, Vice President, Legal and Compliance Officer and Joint Company Secretary, have made voluntary commitments. Do not initiate or direct others to sell or otherwise dispose of company shares directly or indirectly beneficially owned by them, including any shares acquired through the exercise of share options during the prohibited period, for a period of six months, beginning October 29, 2026 (i.e. October 29, 2026 to April 28, 2027, inclusive).

Yingen Bio-B (09606.HK) announced that the company's directors and senior management are confident in the company's long-term value and future development prospects. The board of directors of the company learned that, based on this confidence, Chairman of the Board of Directors, Dr. Zhu Zhongyuan, Executive Director and Chief Financial Officer, Mr. Zhang Shaoren, Executive Director, Dr. Hua Haiqing, Executive Director, Senior Vice President and Chief Financial Officer, Dr. Qiu Yang, Chief Scientific Officer and General Manager of Dualitybio Inc., Dr. Mou Hua, Global Chief Medical Officer, Ms. Si Wen, Executive Director of Human Resources, Mr. Yu Xin, Vice President and Head of Regulatory Affairs, and Ms. Yuan Jiali, Vice President, Legal and Compliance Officer and Joint Company Secretary, have made voluntary commitments. Do not initiate or direct others to sell or otherwise dispose of company shares directly or indirectly beneficially owned by them, including any shares acquired through the exercise of share options during the prohibited period, for a period of six months, beginning October 29, 2026 (i.e. October 29, 2026 to April 28, 2027, inclusive).